Dear Healthcare Professional Letters - Medicine Safety Alerts

• Safety Information
  • Taking Medicines Safely
  • How Does Medsafe Monitor Medicine Safety?
  • How Does Medsafe Monitor Vaccine Safety?
  • Safety Monitoring of Medical Devices
  • Medsafe's Evaluation and Approval Process
• Recalls
  • MORD
  • Quality Concerns Archive
  • Recall Action Definitions
  • Medical Device Suppliers
  • Recall Code
• Safety Communications
  • Medsafe Safety Communications
  • Prescriber Update Articles
  • Dear Healthcare Professional Letters
  • Archive
• Safety Reporting
  • Adverse Reactions to Medicines
  • Device Adverse Event Reporting
  • Report a Problem
• Reports and Promotion
  • Suspected Medicine Adverse Reaction Search
  • ADR Reporting Statistics
  • #MedSafetyWeek Home ► Safety ► Safety Communications ► Dear Healthcare Professional Letters

Revised: 8 April 2026

Safety Information

Dear Healthcare Professional Letters

This section provides copies of letters sent to healthcare professionals
by the therapeutic products industry. These letters detail possible safety
or quality concerns, they are published here on behalf of the industry.
These letters are provided voluntarily and this section may not be comprehensive.

and 32mg Tablets – Supply of French Carton, Foils and
Leaflet |
| 5 March 2026 | Zypine ODT (PDF, 2 pages, 488 KB) | Zypine ODT (Olanzapine) 10 mg
Orodispersible Tablets – Alternative Registered Foils |
| 9 February
2026 | Alecensa (PDF, 2 pages, 145 KB) | Alecensa (alectinib) new adverse
reaction of severe hypertriglyceridaemia |
| 2 February
2026 | Zypine ODT (PDF, 2 pages, 410 KB) | Zypine ODT (Olanzapine) 10 mg
Orodispersible Tablets – Alternative Registered Foils |
| 14 January 2026 | Columvi (PDF, 3 pages, 145 KB) | New important identified risk of haemophagocytic
lymphohistiocytosis with Columvi (glofitamab) |
| 20 November 2025 | Codeine Phosphate Tablets (Noumed) (PDF, 2 pages, 594 KB) | Codeine Phosphate Tablets (Noumed) 15 mg, 30 mg and 60 mg -
Overlabelling of cartons and blister packs due to stock
shortages / out of stock |
| 22 October 2025 | Estradot (PDF, 3 pages, 451 KB) | Recent complaints for Estradot® transdermal patches (25, 50,
75 and 100 mcg/24 hrs) |
| 13 October 2025 | Paxlovid (PDF, 5 pages, 322 KB) | Paxlovid (nirmatrelvir/ritonavir) treatment in patients with
severe renal impairment |
| 24 September 2025 | Risperdal (PDF, 3 pages, 213 KB) | Discontinuation of RISPERDAL® (risperidone) tablets across
all strengths as of 15 December 2025 |
| 22 September 2025 | Ribomustin (PDF, 2 pages, 216 KB) | Discontinuation of RIBOMUSTIN® (bendamustine hydrochloride)
25mg & 100mg powder for infusion as of 30 November 2025 |
| 17 September 2025 | Epilim (PDF, 2
pages, 167 KB) | Updated safety information for valproate: Risk in pregnancy
and women of childbearing potential - lower birth weight
following in utero exposure to valproate |
| 15 September 2025 | Lenalidomide
Viatris (PDF, 2 pages, 379 KB) | Lenalidomide Viatris (lenalidomide) Capsules - NZ-specific
cartons |
| 12 September 2025 | Polivy (PDF, 3 pages, 169 KB) | Infusion site extravasation is a new
identified risk for Polivy (polatuzumab vedotin) |
| 8 September 2025 | Tegretol (PDF, 1 page, 156 KB) | Tegretol (carbamazepine) liquid: limitation of use in
neonates |
| 22 August 2025 | Topiramate Actavis (PDF, 7 pages, 848 KB) | Topiramate: New restrictions to prevent exposure during
pregnancy |
| 14 August 2025 | Vancomycin
(as hydrochloride) (PDF, 1 page, 114 KB) | Vancomycin (as hydrochloride) approval for European
batch to mitigate short-term gap in supply |
| 12 August 2025 | Lenalidomide Viatris (PDF, 2 pages, 306 KB) | Lenalidomide Viatris (lenalidomide) capsules – alternative registered foils |
| 4 August 2025 | Ocrevus (PDF, 3
pages, 219 KB) | Ocrevus (ocrelizumab): liver injury (without findings of viral
hepatitis) |
| 21 July 2025 | CellCept (mycophenolate mofetil) (PDF, 3 pages, 135 KB) | New important identified risk: anaphylactic reaction |
| 14 July 2025 | Lenalidomide Viatris (PDF, 2 pages, 543 KB) | Lenalidomide Viatris capsules (lenalidomide): labelling
exemption for alternative registered foils |
| 26 June 2025 | Risperdal (PDF, 8 pages, 308 KB) | Accidental overdoses in children and adolescents treated with
risperidone 1mg/ml oral solution following administration errors |
| 30 May 2025 | Ventolin (PDF, 2 pages, 200 KB) | Ventolin (salbutamol (as sulfate) aerosol inhaler) - reinforcing
information regarding number of prescribed doses available |
| 22 May 2025 | Estradiol (Mylan) (PDF, 3 pages, 352 KB) | Estradiol Transdermal Patches (Mylan) granted full consent; US
packs will continue to be supplied in the short-term |
| 22 May 2025 | Zyprexa IM (PDF, 2 pages, 226 KB | Zyprexa IM (olanzapine) 10mg powder for injection: Temporary
supply of overseas product |
| 7 April 2025 | Topamax (PDF, 4 pages, 143KB) | Topamax (topiramate): New restrictions to prevent exposure during
pregnancy |
| 31 March 2025 | Venofer (PDF, 2 pages, 314KB) | Important information: VENOFER® (iron sucrose) 20 mg/mL solution
for injection INTERIM PACKAGING |
| 18 March 2025 | GONAL-f (PDF, 1 page, 164 KB) | Editorial changes to the printed volumes on GONAL-f Pen labels. |
| 12 February 2025 | Konakion
MM Paediatric (PDF, 2 pages, 284 KB) | KONAKION MM Paediatric 2mg/0.2mL solution for injection:
Temporary supply of overseas product |
| 28 January 2025 | Imbruvica (PDF,
4 pages, 296 KB) | Newly identified risk of hepatotoxicity (including hepatic
failure) in warnings and precautions section of the Imbruvica NZ
data sheet and consumer medicine information |

See here for archived Dear Healthcare Professional Letters

Related Information

• Data Sheets
• Consumer Medicine Information
• Consumer Information Leaflets
• Product/Application Search
• Suspected Medicine Adverse Reaction Search
• Safety Communications
• Medsafe Online Recalls Database
• Prescriber Update
• Medicines Adverse Reactions Committee